RESUMO
<p><b>OBJECTIVE</b>To examine granulocyte colony stimulating factor (G-CSF) expression in human non-small cell lung cancer (NSCLC) as well as discuss its clinicopathological significance.</p><p><b>METHODS</b>Specimens were obtained from 114 cases (53 cases with granulocyte infiltration) diagnosed pathologically as NSCLC in General Hospital of PLA. Paraffin-embedded tissues from these 114 cases of NSCLC were examined for expression of G-CSF by immunohistochemical staining. Correlation between G-CSF expression and pathological features, clinical manifestation, prognosis of patients with NSCLC was analyzed statistically. All the patients were retrospectively followed-up.</p><p><b>RESULTS</b>Fifty-five of the 114 NSCLC specimens expressed G-CSF, and among these 41 (41/54, 75.9%) were large cell carcinoma, nine (9/30, 30.0%) were adenocarcinoma and five (5/30, 16.7%) were squamous cell carcinoma. The expression was significantly correlated with infiltration of tumor mass by neutrophilic granulocytes, histological type, necrosis, differentiation, lymph node metastases, distant metastases, recurrence and survival period (P < 0.01). There was no significant correlation with primary tumor size (P > 0.05). Logistic multi-factor analysis revealed that necrosis, lymph nodes metastases and distant metastases RR (risk ratio) in G-CSF positive group was 5.57, 6.28 and 5.24 times higher than those of G-CSF negative group (P < 0.05). There were remarkable difference of 5-year survival rates (0 and 12.1% respectively) and survival period (42 and 62 months respectively) between positive and negative groups (P < 0.01).</p><p><b>CONCLUSIONS</b>NSCLC with G-CSF excretion are mainly large cell lung cancer. The pathologic characteristics of these cases with G-CSF expression included poor differentiation, remarkable atypia, prominent necrosis and infiltration of tumor mass by neutrophils or emperipolesis. These tumors are usually more aggressive in biological behavior and have worse prognosis than those without G-CSF expression.</p>
Assuntos
Humanos , Adenocarcinoma , Metabolismo , Patologia , Cirurgia Geral , Carcinoma de Células Grandes , Metabolismo , Patologia , Cirurgia Geral , Carcinoma Pulmonar de Células não Pequenas , Metabolismo , Patologia , Cirurgia Geral , Carcinoma de Células Escamosas , Metabolismo , Patologia , Cirurgia Geral , Seguimentos , Fator Estimulador de Colônias de Granulócitos , Metabolismo , Neoplasias Pulmonares , Metabolismo , Patologia , Cirurgia Geral , Metástase Linfática , Invasividade Neoplásica , Metástase Neoplásica , Recidiva Local de Neoplasia , Estudos Retrospectivos , Taxa de SobrevidaRESUMO
<p><b>OBJECTIVE</b>To evaluate in vitro anti-tumor effect of chemotherapeutic drugs on human gastric cancer cells, and investigate the relationship with Bcl-2 expression.</p><p><b>METHODS</b>Single cell suspension was prepared from fresh gastric cancer tissue and exposed to taxol (Tax), 5-fluorouracil (5-FU), cisplatin (CDDP), adriamycin (ADM), mitomycin (MMC) respectively for 48 hours. Metabolic activity and inhibitory rate of cells were detected by MTT assay. Expression of Bcl-2 was examined with immunohistochemistry.</p><p><b>RESULTS</b>The inhibitory rates of cancer cells exposed to chemotherapeutic drugs were different and Tax, 5-FU, CDDP had remarkably higher rates than ADM and MMC. The lower differentiated gastric cancer cells were more sensitive than the higher ones. Positive expression rate of Bcl-2 was 80% and the positive cells showed resistance to 5-FU, ADM and MMC.</p><p><b>CONCLUSIONS</b>Chemosensitive testing by MTT assay can constitute the prediction for the application of chemotherapeutic drugs individually. Overexpression of Bcl-2 may contribute to multiple drug-resistance of tumors.</p>
Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Antineoplásicos , Farmacologia , Usos Terapêuticos , Sobrevivência Celular , Cisplatino , Farmacologia , Usos Terapêuticos , Doxorrubicina , Farmacologia , Usos Terapêuticos , Ensaios de Seleção de Medicamentos Antitumorais , Fluoruracila , Farmacologia , Usos Terapêuticos , Mitomicina , Farmacologia , Usos Terapêuticos , Mitomicinas , Farmacologia , Usos Terapêuticos , Paclitaxel , Farmacologia , Usos Terapêuticos , Proteínas Proto-Oncogênicas c-bcl-2 , Metabolismo , Neoplasias Gástricas , Tratamento Farmacológico , Metabolismo , Patologia , Células Tumorais CultivadasRESUMO
<p><b>OBJECTIVE</b>To evaluate in vitro antitumor effects of chemotherapeutic drugs, and investgate the relationship with expression of hTERT mRNA in human gastric cancer tissues.</p><p><b>METHODS</b>Fresh samples of gastric cancer obtained from operation room were prepared to single-cell suspension (3 x 10(5) to 5 x 10(5) cells ml(-1)) and were separately exposed to taxol (TAX), cisplatin (CDDP), 5-fluorouracil (5-Fu), adriamycin (ADM), mitomycin (MMC) for 48 hours. Metabolic activity and inhibitory rate of the cells were determined by trypan blue exclusion and MTT assay. Expression of hTERT mRNA was detected by in situ hybridization (ISH).</p><p><b>RESULTS</b>The inhibition rate of cancer cells exposed to chemotherapeutic drugs was different, and that of TAX, CDDP, 5-Fu was significantly higher than that of ADM and MMC. The positive rate of hTERT mRNA expression was 90.0% (54/60) and positive cells showed resistance to 5-Fu and ADM.</p><p><b>CONCLUSION</b>Overexpression of hTERT mRNA may contribute to primary drug-resistance of tumors. Chemosensitivity tests by MTT assay may contribute to prediction of effectness in applying chemotherapeutic drugs and identify drug-resistant cases.</p>